REPLICor Presenting at Metabolic Diseases Summit
Laval, Quebec – June 21, 2006 -- REPLICor announced today that Dr. Andrew Vaillant, REPLICor's Chief Scientific Officer, will present at the 5th International Metabolic Diseases Summit 2006 at the Hilton SanDiego / Del Mar in SanDiego, California, on July 24-25th, 2006,. In his 30-minute presentation, Dr.Vaillant will provide an update of REPLICor’s product scientific developments in treating hypercholesterolemia, obesity and other metabolic disorders and will review REPLICor’s R&D goals for 2006.
About REPLICor:
REPLICor is a biopharmaceutical company developing applications for its novel DNA-based technology platform. REPLICor’s technology is based on the discovery that oligonucleotides have sequence independent and size dependent activities as amphipathic polymers with multiple potential clinical applications.
REPLICor has demonstrated that its two lead compounds, REP 9 and REP 9C, have the ability to interact with a wide variety of targets that are present in a variety of disease states including viral infections, metabolic disorders, amyloid related diseases and inflammatory diseases. They have also been shown to be well tolerated in multiples animal studies. REP 9 and REP 9C can readily be synthesized in large quantities in cGMP facilities. The company business strategy is to enter into alliances with major biopharmaceutical companies in order to further develop and market its products.
For more information:
Andrew Vaillant PhD, CSO
REPLICor Inc.
450-688-6068